Follow on Google News News By Tag * Substance Abuse Therapeutics * Anti-Smoking Legislation * Pharmaceuticals_and_healthcare * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Substance Abuse Therapeutics Market to 2018Anti-Smoking Legislation Vital for Nicotine Addiction to go up in Smoke, says Report
By: Rajesh Gunnam The new report* argues that the effectiveness of current pharmaceutical treatments depends as much on enforced legislation, such as smoking bans, and support from healthcare providers as an individual’s willingness to quit. According to the World Health Organization (WHO), up to half of all ‘lifelong’ GBI Research claims that the prevalent population for nicotine addiction stood at 136.7 million in 2011, while the ‘diagnosed’ For Sample Pages, please click or add the below link to your browser: http://www.gbiresearch.com/ Popular Nicotine Replacement Therapies (NRTs) are conveniently available over-the-counter and account for 75% of all smoking cessation therapies sold worldwide, with patches, gum, lozenges, sprays and inhalers available to deliver doses of nicotine and reduce the effects of withdrawal. FDA-approved prescription medications for smoking cessation include the nicotine receptor agonist Chantix (varenicline) The increasing emergence of smokeless electronic ‘e-cigarette’ The report states that increasing numbers of patients seeking treatment are being supported by healthcare campaigns around the world. Government efforts are evident in the UK, where the NHS Stop Smoking service enabled over half a million patients to access smoking cessation therapy during April 2011- December 2011 alone. The report goes on to indicate that future revenues will be made from smoking cessation therapies in countries where legislation and healthcare campaigns are not yet present. South East Asia represents a huge potential market for the next 15 years, as a very high smoking prevalence rate is contrasted with the lack of an established market for NRT or anti-smoking products. GBI Research healthcare analyst, Amy Baker, said: “This market is as yet largely untapped because of cultural attitudes to smoking and a lack of public health efforts; but, should any companies in the future crack the Asian markets, it will offer a massive opportunity.” The global nicotine addiction therapeutics market was estimated at $4.5 billion in 2011, indicating a CAGR of 3.1% between 2004 and 2011. The value is expected to reach $6.2 billion in 2018, following growth at a CAGR of 4.5% between 2011 and 2018. The report provides insights into the substance abuse therapeutics market, including market forecasts up to 2018, and an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse. It additionally gives insights into the substance abuse therapeutics R&D pipeline, and analyzes the competitive landscape through the analysis of M&A and licensing deals. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/ Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: End
Account Email Address Account Phone Number Disclaimer Report Abuse Page Updated Last on: Aug 29, 2012
|
|